US Pharma MarketingThe post Kailera points to Phase III oral obesity drug data as it tees up Foundayo rivalry appeared first on Clinical Trials Arena.
Kailera points to Phase III oral obesity drug data as it tees up Foundayo rivalry
Kailera’s in-licensed oral weight loss drug, HRS-7535, is currently in a global Phase II study for obesity. Kailera’s in-licensed oral weight loss drug is currently in a global Phase II study for obesity. Hengrui Pharma has reported positive outcomes for a duo of Phase III trials evaluating its oral weight loss drug, HRS-7535, potentially having positive readthroughs for Kailera’s global Phase II programme on the drug. Credit: New Africa / Shutterstock.com. Kailera Therapeutics’ bet on Hengui Pharma’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA) appears to be paying off following two late-stage wins in obesity and type 2 diabetes (T2D)…
Kailera’s in-licensed oral weight loss drug, HRS-7535, is currently in a global Phase II study for obesity.
Source: Clinical Trials Arena